 Skye Bioscience inc OTCQB:SKYE announced that it has completed a good laboratory practice GLP nonclinical toxicology study of its SBI-100 ophthalmic nanoemulsion in support of the companys planned Phase 1 first-in-human clinical trial in Australia. The San Diego-based company said that the purpose of this study was to evaluate the ocular toxicity and toxicokinetics of SBI-100 ophthalmic nanoemulsion when administered to rabbits either two or three times daily at multiple doses by topical ocular administration for fourteen consecutive days. 